Rapid Production of Physiologic Dendritic Cells (phDC) for Immunotherapy

Hanlon, Douglas; Sobolev, Olga; Han, Patrick; Ventura, Alessandra; Vassall, Aaron; Kibbi, Nour; Yurter, Alp; Robinson, Eve; Filler, Renata; Tatsuno, Kazuki; Edelson, Richard L.

doi:10.1007/978-1-0716-0203-4_11

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dendritic cells are professional antigen-presenting cells (APC) that sense antigens in barrier tissues, migrate to lymphoid organs to prime naïve T cells becoming tolerogenic or immunogenic antigen-specific effector cells. Consequently, DC induced by ECP are instrumental for antigenspecific T cell-mediated immunity and tolerance (129). The change in DC morphology and function has been demonstrated in several different diseases treated by ECP and is likely to be the primary biological effect of the treatment (Figure 2).…”

Section: Immunomodulatory Effects Of Ecp On Circulating Vstissue-resi...mentioning

confidence: 99%

Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers

et al. 2023

View full text Add to dashboard Cite

Haematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant haematological diseases. Despite continuous improvements in pre- and post-transplantation procedures, the applicability of allo-HSCT is limited by life-threatening complications such as graft-versus-host disease (GvHD), engraftment failure, and opportunistic infections. Extracorporeal photopheresis (ECP) is used to treat steroid resistant GvHD with significant success. However, the molecular mechanisms driving its immunomodulatory action, whilst preserving immune function, require further understanding. As ECP is safe to administer with few significant adverse effects, it has the potential for earlier use in the post-HSCT treatment of GvHD. Thus, further understanding the immunomodulatory mechanisms of ECP action may justify more timely use in clinical practice, as well as identify biomarkers for using ECP as first line or pre-emptive GvHD therapy. This review aims to discuss technical aspects and response to ECP, review ECP as an immunomodulatory treatment modality for chronic GvHD including the effect on regulatory T cells and circulating vs. tissue-resident immune cells and consider the importance of emerging biomarkers for ECP response.

show abstract

Section: Immunomodulatory Effects Of Ecp On Circulating Vstissue-resi...mentioning

confidence: 99%